12 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 5 Phase 2, 3 Not applicable, 3 Phase 1, 3 Phase 4, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Not applicable | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 4 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 2 | Completed 2 |
Follow Hypercholesterolemia, Autosomal Dominant, 3: new trials by email Literature Review of Hypercholesterolemia, Autosomal Dominant, 3 trials Research Report on Hypercholesterolemia, Autosomal Dominant, 3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia | Phase 4 | Not yet recruiting | Amgen | 308 | 2027-01-31 | 2026-09-21 |
| CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS Evolocumab, Serial photon-counting coronary computed tomography angiography, Standard Lipid-Lowering Therapy - Coronary, Coronary Artery Disease | Phase 4 | Recruiting | West China Hospital | 232 | 2025-11-19 | 2026-10-07 |
| A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years AZD0780, Metformin - Healthy Participants | Phase 1 | Completed | AstraZeneca | 14 | 2025-11-10 | 2026-01-09 |
| Genetic Testing and Motivational Counseling for FH Genetic Testing, Motivational Counseling, Lipid analysis - Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1 | Not applicable | Active not recruiting | National Medical Research Center for Therapy and Preventive Medicine | 180 | 2020-06-15 | 2024-12-17 |
| Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids Omega-3 fatty acids - Type 2 Diabetes, Inflammation | Not applicable | Recruiting | Institut de Recherches Cliniques de Montreal | 48 | 2019-12-19 | 2026-03-12 |
| Impact of Evolocumab in Cardiac Transplant Patients With CAV Evolocumab - Heart Transplant | Phase 2 | Completed | University of Nebraska | 26 | 2019-07-15 | 2024-06-03 |
| Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia Evolocumab, Placebo - Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection | Phase 3 | Completed | Amgen | 467 | 2017-05-22 | 2022-07-22 |
| Alirocumab in Patients With Acute Myocardial Infarction alirocumab, placebo - Myocardial Infarction, Hypercholesterolemia | Phase 4 | Completed | Virginia Commonwealth University | 20 | 2017-01-01 | 2019-09-06 |
| Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)) Evolocumab, Placebo - Subjects With Hyperlipidemia, Dyslipidemia | Phase 3 | Completed | Amgen | 129 | 2016-04-14 | 2022-09-23 |
| The Effect of Resistance Training on Proprotein Subtilisin Convertase Kexin 9 Level After Coronary Bypass Surgery resistance training, aerobic training - Coronary Artery Disease | Not applicable | Completed | National Cardiovascular Center Harapan Kita Hospital Indonesia | 87 | 2016-02-10 | 2020-01-21 |
| Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study Evolocumab, Placebo - Hypercholesterolemia, Familial | Phase 2 | Completed | Amgen | 168 | 2011-08-02 | 2022-11-15 |
| Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects Evolocumab, Ezetimibe, Placebo to Evolocumab - Hyperlipidemia | Phase 2 | Completed | Amgen | 160 | 2011-07-28 | 2022-11-07 |
| Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels Evolocumab, Ezetimibe, Placebo to Evolocumab - Hyperlipidemia | Phase 2 | Completed | Amgen | 411 | 2011-07-06 | 2022-11-08 |
| Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins LGT209 50 mg, LGT209 300 mg, Placebo - Hypercholesterolemia, LDL Cholesterol | Phase 1 | Completed | Novartis Pharmaceuticals | 25 | 2011-07-01 | 2020-12-17 |
| LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy Evolocumab, Placebo to Evolocumab - Hyperlipidemia | Phase 2 | Completed | Amgen | 631 | 2011-07-01 | 2022-11-15 |
| Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia LGT209, Placebo - Hypercholesterolemia | Phase 1 | Completed | Novartis Pharmaceuticals | 74 | 2010-12-01 | 2013-12-10 |
Hypercholesterolemia (8) · Hyperlipidemias (5) · Coronary Artery Disease (3) · Dyslipidemias (3) · Hyperlipoproteinemia Type II (3) · Inhibition, Psychological (2) · Acute Coronary Syndrome (1) · Diabetes Mellitus, Type 2 (1) · HIV Infections (1) · Hyperlipoproteinemia Type III (1) · Inflammation (1) · Insulin Resistance (1) · Medication Adherence (1) · Myocardial Infarction (1)
Lipid Metabolism Disorders (13) · Metabolic Diseases (13) · Nutritional and Metabolic Diseases (13) · Dyslipidemias (10) · Hyperlipidemias (7) · Cardiovascular Diseases (4) · Heart Diseases (4) · Myocardial Ischemia (4) · Vascular Diseases (4) · Arterial Occlusive Diseases (3) · Arteriosclerosis (3) · Behavior (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Coronary Disease (3) · Genetic Diseases, Inborn (3)
evolocumab (9) · Ezetimibe (2) · Atorvastatin (1) · Diet (1) · Fatty Acids, Omega-3 (1) · Genetic Testing (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Metformin (1) · Motivational Interviewing (1) · Referral and Consultation (1) · Resistance Training (1) · Simvastatin (1) · alirocumab (1)
Amgen (7) · Novartis Pharmaceuticals (2) · AstraZeneca (1) · Institut de Recherches Cliniques de Montreal (1) · National Cardiovascular Center Harapan Kita Hospital Indonesia (1) · National Medical Research Center for Therapy and Preventive Medicine (1) · University of Nebraska (1) · Virginia Commonwealth University (1) · West China Hospital (1)
United States (10) · Canada (6) · Australia (3) · Belgium (3) · Denmark (3) · Spain (2) · Brazil (1) · China (1) · Czechia (1) · Finland (1) · France (1) · Greece (1) · Hungary (1) · Italy (1) · Netherlands (1)
Alexandra Ershova, MD, PhD (1) · Alexey Meshkov, MD, PhD (1) · Antonio Abbate, MD, PhD (1) · Bambang Dwiputra, MD (1) · Douglas A Stoller, MD, PhD (1) · May Faraj, PDt, PhD (1) · Yong He (1)
PMID 33078867, PMID 10720604, PMID 12730697, PMID 12937035, PMID 16554528, PMID 16826016, PMID 17080197, PMID 17211497, PMID 17452316, PMID 17881241, PMID 18033751, PMID 18547466, PMID 19628659, PMID 20643803, PMID 23128163, PMID 23176104, PMID 23414745, PMID 23862065, PMID 23884353, PMID 23973703, PMID 25128757, PMID 25520374, PMID 26081791, PMID 27760527, PMID 27771273, PMID 27919352, PMID 32268367, PMID 32393252, PMID 37801454, PMID 37946122
2015 (2)